IN2014MU00455A - - Google Patents

Download PDF

Info

Publication number
IN2014MU00455A
IN2014MU00455A IN455MU2014A IN2014MU00455A IN 2014MU00455 A IN2014MU00455 A IN 2014MU00455A IN 455MU2014 A IN455MU2014 A IN 455MU2014A IN 2014MU00455 A IN2014MU00455 A IN 2014MU00455A
Authority
IN
India
Prior art keywords
preparation
present disclosure
disclosure relates
novel crystalline
dolutegravir sodium
Prior art date
Application number
Other languages
English (en)
Inventor
Ramakoteswara Rao Jetti
Satish Beeravelly
Madhu Murthy Nadella
Haribabu Nandipati
Original Assignee
Mylan Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mylan Lab Ltd filed Critical Mylan Lab Ltd
Priority to EP15710893.7A priority Critical patent/EP3102582A1/en
Priority to CA2938103A priority patent/CA2938103C/en
Priority to IN455MU2014 priority patent/IN2014MU00455A/en
Priority to BR112016018056A priority patent/BR112016018056A2/pt
Priority to US15/114,991 priority patent/US10087193B2/en
Priority to PCT/IB2015/050841 priority patent/WO2015118460A1/en
Priority to AU2015215630A priority patent/AU2015215630B2/en
Publication of IN2014MU00455A publication Critical patent/IN2014MU00455A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
IN455MU2014 2014-02-07 2015-02-04 IN2014MU00455A (pl)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP15710893.7A EP3102582A1 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
CA2938103A CA2938103C (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
IN455MU2014 IN2014MU00455A (pl) 2014-02-07 2015-02-04
BR112016018056A BR112016018056A2 (pt) 2014-02-07 2015-02-04 Formas cristalinas de dolutegravir sódico e processos para suas preparações
US15/114,991 US10087193B2 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
PCT/IB2015/050841 WO2015118460A1 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium
AU2015215630A AU2015215630B2 (en) 2014-02-07 2015-02-04 Crystalline forms of dolutegravir sodium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN455MU2014 IN2014MU00455A (pl) 2014-02-07 2015-02-04

Publications (1)

Publication Number Publication Date
IN2014MU00455A true IN2014MU00455A (pl) 2015-09-25

Family

ID=53777379

Family Applications (1)

Application Number Title Priority Date Filing Date
IN455MU2014 IN2014MU00455A (pl) 2014-02-07 2015-02-04

Country Status (7)

Country Link
US (1) US10087193B2 (pl)
EP (1) EP3102582A1 (pl)
AU (1) AU2015215630B2 (pl)
BR (1) BR112016018056A2 (pl)
CA (1) CA2938103C (pl)
IN (1) IN2014MU00455A (pl)
WO (1) WO2015118460A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2956662A1 (en) * 2014-07-29 2016-02-04 Lek Pharmaceuticals D.D. Novel hydrates of dolutegravir sodium
ES2969437T3 (es) * 2015-08-19 2024-05-20 Laurus Labs Ltd Polimorfos novedosos de dolutegravir y de sales del mismo
WO2017046131A1 (en) * 2015-09-15 2017-03-23 Ratiopharm Gmbh Processes for preparing solid state forms of dolutegravir sodium
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
WO2019003150A2 (en) * 2017-06-30 2019-01-03 Viiv Healthcare Company ASSOCIATION, USES AND THERAPEUTIC DIAGRAMS
EP3661940A1 (en) 2017-09-07 2020-06-10 Cipla Limited New polymorphs of dolutegravir sodium
US20220112212A1 (en) * 2019-02-05 2022-04-14 Msn Laboratories Private Limited, R&D Center Novel crystalline polymorphs of sodium (4r,12as)-9-{[(2,4-difluorophenyl) methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2h-pyrido [1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate and process for preparation thereof
CN114213432B (zh) * 2021-12-31 2023-02-17 瑞孚信江苏药业股份有限公司 度鲁特韦的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2376080B1 (en) 2008-12-11 2017-09-13 Shionogi&Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2013038407A1 (en) 2011-09-14 2013-03-21 Mapi Pharma Ltd. Amorphous form of dolutegravir
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) * 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof

Also Published As

Publication number Publication date
CA2938103A1 (en) 2015-08-13
WO2015118460A1 (en) 2015-08-13
EP3102582A1 (en) 2016-12-14
US10087193B2 (en) 2018-10-02
AU2015215630A1 (en) 2016-09-22
AU2015215630B2 (en) 2018-08-16
BR112016018056A2 (pt) 2017-08-08
CA2938103C (en) 2021-08-10
US20160347766A1 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
PH12016501763A1 (en) Multispecific antibodies
IL264454A (en) Novel compositions, uses and methods for making them
IN2014MU00455A (pl)
JO3487B1 (ar) تخليق كوبانليسيب وملح الدايهيدروكلوريد الخاص به
MX2017001487A (es) Sofosbuvir en forma cristalina y proceso para su preparacion.
IN2013MU00646A (pl)
HUE055687T2 (hu) Eljárás D-arginil-2,6-dimetil-L-tirozil-L-lizil-L-fenilalaninamid elõállítására
MX2017011389A (es) Proceso para la preparacion de 3-cloro-2-vinilfenilsulfonatos.
PL3160984T3 (pl) Sposób wytwarzania d-arginylo-2,6-dimetylo-l-tyrozylo-l-lizylol- fenyloalaninoamidu
IN2014CH00151A (pl)
IN2013MU01113A (pl)
MX2016015624A (es) Proceso para la preparacion de derivados de tiazol.
IN2014CH00304A (pl)
PL2964607T3 (pl) Sposób wytwarzania halogeno-n,n-dimetylobenzyloamin
MX2016015623A (es) Proceso para la preparacion de derivados dihidroisoxazol.
GB2561089B (en) Process for the preparation of 17beta-hydroxy-des-a-androst-9, 10-en-5-one
TW201612142A (en) Process for preparing 3-chloro-2-vinylphenol
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
MX2016002186A (es) Proceso para preparar dronedarona y sales de la misma.
IN2013CH05865A (pl)
MX2017011388A (es) Proceso para la preparacion de derivados de fenilisoxazolina sustituida.
IN2013MU02771A (pl)
IN2013MU01966A (pl)
IN2013CH00453A (pl)
TW201613927A (en) Method for preparation of substituted imidazopyridazines